Oramed Pharmaceuticals, Inc (ORMP) saw an uptrend of 6.61% in the recent trading with $2.58 being its most recent. The current price level -16.50% lower than the highest price of $3.09 marked by the stock while trading over the past 52-weeks, whereas it is 41.76% higher than the lowest price of $1.82 the company dropped to over past 52-weeks. The latest news story on ORMP appeared in (PR Newswire) under the title “Oramed Reports Fiscal Third Quarter 2025 Financial Results”.
Squeezing the time span to 30 day period shows us the stock is currently trading -2.64% below one month high and is +23.44% above of the lowest during that time. Looking into the simple moving average, Oramed Pharmaceuticals, Inc (ORMP)’s stock stands at a SMA-50 of $2.39 while that of 5-day is reading $2.46.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and ORMP’s SMA-200 as of now is $2.26.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Hold by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 3.00 for the stock.
Oramed Pharmaceuticals, Inc Earnings – What Happened With ORMP
Coming around sales and income figures on ORMP Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Oramed Pharmaceuticals, Inc (ORMP) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of -1,200.00% for net revenue.
ORMP – Oramed Pharmaceuticals, Inc Stock Earnings Estimates
The perspective of Oramed Pharmaceuticals, Inc (NASDAQ:ORMP)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.02 for stock’s EPS in the current quarter. Oramed Pharmaceuticals, Inc (ORMP) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of -1,200.00% for net revenue. Company’s EPS for the last quarter was -0.26.
Oramed Pharmaceuticals, Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 40.84 million. ORMP does have institutional investors; and they hold 18.61% of the stock.
As on 2024-06-30, MURCHINSON LTD. was the top most holder in Oramed Pharmaceuticals, Inc (NASDAQ:ORMP) with an ownership of 1.7 million shares of the company or 4.1504 of the stake worth $4.37 million. The filing also reveals BML CAPITAL MANAGEMENT, LLC as the second largest holder in the company with a control over 3.2936 of the outstanding shares. Its stake is worth $3.47 million for having 1.35 million shares in hand.
BOOTHBAY FUND MANAGEMENT, LLC also came holding a key position in the company during the recent quarter and it now holds 2.0142 of the outstanding shares. With this there are now 54.0 institutions which have possession in ORMP’s shares.
Key Metrics for ORMP
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Oramed Pharmaceuticals, Inc has a debt to equity ratio of 0.00.
Technical Analysis of Oramed Pharmaceuticals, Inc (NASDAQ:ORMP) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Oramed Pharmaceuticals, Inc (ORMP), we notice that the stock’s 20-day average volume is at 224,770 shares and 50% of short term indicators are suggesting the stock as Buy. Medium term indicators at an average of 100% are spotting the stock at Buy with its 50-day average volume of 162,078 shares. And to end, ORMP’s 100-day average volume is 120,122 shares with 100% of the long-term indicators pointing towards Buy for the stock.
